BioTime to Report Fourth Quarter and Full Year 2018 Financial Results on March 14th, 2019
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 7, 2019--
Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology
company focused on degenerative diseases, today announced that it will
report its fourth quarter and full year 2018 financial and operating
results on Thursday, March 14th, 2019, following the close of
the U.S. financial markets. BioTime management will also host a
conference call and webcast on Thursday, March 14th, 2019, at
4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth
quarter and full year 2018 financial results and to provide a business
Interested parties may access the conference call by dialing (866)
888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere
outside the U.S. and should request the “BioTime Inc. Call”. A live
webcast of the conference call will be available online in the Investors
section of BioTime’s website. A replay of the webcast will be available
on BioTime’s website for 30 days and a telephone replay will be
available through March 21st, 2019, by dialing (855)
859-2056 from the U.S. and Canada and (404) 537-3406 from elsewhere
outside the U.S. and entering conference ID number 1091719.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on the
development and commercialization of novel therapies for the treatment
of degenerative diseases. BioTime’s pipeline is based on two platform
technologies which encompass cell replacement and cell/drug delivery.
BioTime’s lead cell replacement product candidate is OpRegen®,
a retinal pigment epithelium transplant therapy in Phase 2 development
for the treatment of dry age-related macular degeneration, the leading
cause of blindness in the developed world. BioTime’s lead cell delivery
clinical program is Renevia®, an investigational medical
device being developed as an alternative for whole adipose tissue
transfer procedures. BioTime common stock is traded on the NYSE American
and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com.
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotime.com.